Orchard Therapeutics Plc Quick Ratio (ORTX) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Orchard Therapeutics Plc  (NASDAQ: ORTX)

Orchard Therapeutics Plc's Quick Ratio

ORTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.44 below Orchard Therapeutics Plc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 115 other companies have achieved higher Quick Ratio than Orchard Therapeutics Plc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 770 to 1157.

Explain Quick Ratio?
How much Cash & cash equivalents ORTX´s has?
What are ORTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORTX Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -11.33 % 8.3 % 15.75 % 22.44 % 33.38 %
Y / Y Cash & cash equivalent Change -83.98 % -77.6 % 14.09 % 22.02 % 97.16 %
Quick Ratio MRQ 0.44 0.64 1.1 1.09 2.43
ORTX's Total Ranking # 1157 # 770 # 1102 # 793 # 1052
Seq. Current Liabilities Change -10.99 % 7.55 % -11.05 % 4.13 % 8.72 %
Seq. Cash & cash equivalent Change -38.67 % -37.75 % -10.14 % -53.31 % -14.24 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 116
Healthcare Sector # 550
Overall Market # 1157


Quick Ratio Statistics
High Average Low
35.23 9.82 2.37
(Mar 31 2019)   (Dec 31 2022)




Financial Statements
Orchard Therapeutics Plc's Current Liabilities $ 54 Millions Visit ORTX's Balance sheet
Orchard Therapeutics Plc's Cash & cash equivalent $ 23 Millions Visit ORTX's Balance sheet
Source of ORTX's Sales Visit ORTX's Sales by Geography


Cumulative Orchard Therapeutics Plc's Quick Ratio

ORTX's Quick Ratio for the trailling 12 Months

ORTX Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 7.84 % 19.38 % 25.48 % 20.79 % 14.03 %
Y / Y Cash & cash equivalent TTM Growth -55.16 % -11.39 % 57.38 % 42.18 % -3.99 %
Quick Ratio TTM 0.82 1.32 1.91 1.94 1.98
Total Ranking TTM # 4122 # 3707 # 2983 # 2093 # 777
Seq. Current Liabilities TTM Growth -2.86 % 1.96 % 3.35 % 5.35 % 7.54 %
Seq. Cash & cash equivalent TTM Growth -39.11 % -29.64 % 1.73 % 2.89 % 20.33 %

Quick ratio ranking by company, industry and sector >> Back to ORTX Financial Strength Comparisons >> Go to Compare ORTX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ORTX's Current Liabilities to $53.50 millions, cumulative Quick Ratio to 0.82 below the ORTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 175 other companies have achieved higher Quick Ratio than Orchard Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3707 to 4122.

Explain Quick Ratio?
How much Cash & cash equivalents ORTX´s has?
What are ORTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 176
Healthcare Sector # 1081
Within the Market # 4122


trailing twelve months Quick Ratio Statistics
High Average Low
7.77 5.33 2.57
(Sep 30 2019)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Sangamo Therapeutics Inc   1.17 $ 56.514  Millions$ 48.482  Millions
Bio techne Corp  1.16 $ 148.663  Millions$ 127.754  Millions
Sqz Biotechnologies Company  1.15 $ 10.193  Millions$ 8.832  Millions
Bluebird Bio Inc   1.10 $ 174.293  Millions$ 158.957  Millions
Tectonic Therapeutic Inc   1.07 $ 6.330  Millions$ 5.912  Millions
Meiragtx Holdings Plc  1.00 $ 63.365  Millions$ 63.514  Millions
Calidi Biotherapeutics Inc   0.93 $ 10.147  Millions$ 10.873  Millions
Taysha Gene Therapies Inc   0.91 $ 164.278  Millions$ 180.451  Millions
Tarsus Pharmaceuticals Inc   0.87 $ 20.213  Millions$ 23.249  Millions
Champions Oncology Inc   0.82 $ 5.513  Millions$ 6.707  Millions
Fate Therapeutics Inc   0.81 $ 33.334  Millions$ 41.333  Millions
Valneva Se  0.79 $ 141.210  Millions$ 177.927  Millions
Evaxion A  0.75 $ 6.398  Millions$ 8.489  Millions
Acorda Therapeutics Inc   0.73 $ 32.468  Millions$ 44.716  Millions
Dbv Technologies S a   0.72 $ 18.927  Millions$ 26.298  Millions
Mink Therapeutics Inc   0.62 $ 6.399  Millions$ 10.394  Millions
Scinai Immunotherapeutics Ltd  0.56 $ 1.000  Millions$ 1.780  Millions
Biocardia Inc   0.55 $ 1.835  Millions$ 3.330  Millions
Coherus Oncology inc   0.55 $ 131.077  Millions$ 239.659  Millions
Agenus Inc  0.54 $ 106.305  Millions$ 198.356  Millions
Outlook Therapeutics Inc   0.50 $ 23.392  Millions$ 46.732  Millions
Protalix Biotherapeutics inc   0.47 $ 20.408  Millions$ 43.359  Millions
Novavax inc   0.44 $ 651.104  Millions$ 1,468.590  Millions
Elutia Inc   0.44 $ 14.517  Millions$ 32.976  Millions
Zeo Scientifix Inc   0.44 $ 1.764  Millions$ 4.010  Millions
Orchard Therapeutics Plc  0.44 $ 23.472  Millions$ 53.501  Millions
Xtant Medical Holdings Inc   0.40 $ 8.664  Millions$ 21.921  Millions
Aptose Biosciences Inc   0.30 $ 3.687  Millions$ 12.380  Millions
Cyclo Therapeutics Inc   0.27 $ 1.802  Millions$ 6.605  Millions
Sab Biotherapeutics Inc   0.26 $ 2.425  Millions$ 9.211  Millions

Date modified: 2026-09-26T07:35:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.